Yes, unfractionated heparin should be administered during primary PCI for STEMI
For patients with STEMI undergoing primary PCI who have already received aspirin and a P2Y12 inhibitor, unfractionated heparin (UFH) administration is a Class I recommendation with Level of Evidence C 1, 2, 1, 2, 1. This is standard anticoagulant therapy required during the procedure, regardless of prior antiplatelet therapy.
Dosing Algorithm
The heparin dose must be adjusted based on whether you plan to use a glycoprotein IIb/IIIa inhibitor:
If GP IIb/IIIa inhibitor is planned:
If NO GP IIb/IIIa inhibitor is planned:
- Administer 70-100 U/kg IV bolus
- Target ACT: 250-300 seconds (HemoTec device) or 300-350 seconds (Hemochron device) 1, 2
Additional boluses should be given as needed to maintain therapeutic ACT levels throughout the procedure 1, 2, 1, 2, 1.
Monitoring Requirements
- Check ACT at baseline before heparin administration
- Recheck ACT approximately every 4 hours during continuous infusion 3
- Adjust dosing based on ACT results to maintain therapeutic range
- Monitor platelet counts, hematocrit, and occult blood in stool periodically 3
Alternative Anticoagulant Option
Bivalirudin is an acceptable alternative with a Class I, Level of Evidence B recommendation 1, 2, 1, 2, 1:
- Dose: 0.75 mg/kg IV bolus, then 1.75 mg/kg/h infusion
- Can be used with or without prior UFH treatment
- Class IIa recommendation: Bivalirudin is preferred over UFH plus GP IIb/IIIa inhibitor in patients at high bleeding risk 1, 2
The 2019 ESC guidelines similarly recommend anticoagulation for all patients undergoing PCI, with UFH as the standard option 4.
Critical Pitfalls to Avoid
Do NOT use fondaparinux as sole anticoagulant - This is a Class III: Harm recommendation due to increased catheter thrombosis risk 1, 2
Weight-based dosing variability: Recent evidence shows significant variability in heparin response, with obese patients requiring lower weight-adjusted doses 5. Only 49% of patients achieve target ACT with the initial recommended bolus, so ACT monitoring is essential.
Do NOT switch between UFH and enoxaparin - Crossover is not recommended (Class III) 4
Confirm correct vial strength - Fatal medication errors have occurred from confusion between different heparin concentrations 3
Evidence Nuances
While bivalirudin reduces major bleeding by approximately 40-48% compared to UFH plus GP IIb/IIIa inhibitors 6, 7, it may increase acute stent thrombosis risk. A 2014 meta-analysis found that UFH plus GP IIb/IIIa inhibitor was most efficacious for preventing major adverse cardiovascular events, while bivalirudin was safest for bleeding 7. However, much of bivalirudin's bleeding benefit is explained by reduced GP IIb/IIIa inhibitor use rather than the anticoagulant itself 6.
The 2025 ACC/AHA guidelines continue to support both UFH and bivalirudin as acceptable options, with choice based on individual bleeding and thrombotic risk assessment 8.